MedTrace Logo

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

NCT02462083 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 555

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the long-term safety of IDP-118 lotion.

Conditions

Interventions

DRUG

IDP-118 Lotion

IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.

Sponsors & Collaborators

  • Dow Pharmaceutical Sciences

    collaborator INDUSTRY

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Binu J Alexander · Valeant Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-11
Primary Completion
2017-01-31
Completion
2017-04-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462083 on ClinicalTrials.gov